Recommended Topic Related To:

Lorabid

"Infection with Streptococcus pneumoniae bacteria can make children very sick.

It causes blood infections, pneumonia, and bacterial meningitis, mostly in young children. (Meningitis is an infection of the covering of the brain.) Pne"...

Lorabid

Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

Indications
Dosage
How Supplied

INDICATIONS

Loracarbef is indicated in the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (As recommended dosages, durations of therapy, and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific recommendations.)

Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis caused by S. pneumoniae, H. influenzae(including b-lactamase-producing strains), or M. catarrhalis (including b-lactamase-producing strains).

Acute Bacterial Exacerbations of Chronic Bronchitis: caused by S. pneumoniae, H. influenzae (including b-lactamase-producing strains), or M. catarrhalis (including b-lactamase-producing strains).

Pneumonia: caused by S. pneumoniae or H. influenzae (non-b-lactamase-producing strains only). Data are insufficient at this time to establish efficacy in patients with pneumonia caused by b-lactamase-producing strains of H. influenzae.

Upper Respiratory Tract: Otitis Media† caused by S. pneumoniae, H. influenzae (including b-lactamase-producing strains), M. catarrhalis (including b-lactamase-producing strains), or S. pyogenes.

Acute Maxillary Sinusitis:† caused by S. pneumoniae, H. influenzae (non-b-lactamase-producing strains only), or M. catarrhalis (including b-lactamase-producing strains). Data are insufficient at this time to establish efficacy in patients with acute maxillary sinusitis caused by b-lactamase-producing strains of H. influenzae.

† NOTE: In a patient population with significant numbers of b-lactamase-producing organisms, loracarbef's clinical cure and bacteriological eradication rates were somewhat less than those observed with a product containing a b-lactamase inhibitor. Loracarbef's decreased potential for toxicity compared to products containing b-lactamase inhibitors along with the susceptibility patterns of the common microbes in a given geographic area should be taken into account when considering the use of an antimicrobial (see CLINICAL STUDIES.)

Pharyngitis and Tonsillitis: caused by S. pyogenes. (The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin administered by the intramuscular route. Loracarbef is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of loracarbef in the subsequent prevention of rheumatic fever are not available at present.) For information on use in pediatric patients, see PRECAUTIONS, Pediatric Use.

Skin and Skin Structure: Uncomplicated Skin and Skin Structure Infections caused by S. aureus (including penicillinase-producing strains) or S. pyogenes. Abscesses should be surgically drained as clinically indicated.

Urinary Tract: Uncomplicated Urinary Tract Infections (cystitis) caused by E. coli or S. saprophyticus*.

NOTE: In considering the use of loracarbef in the treatment of cystitis, loracarbef's lower bacterial eradication rates and lower potential for toxicity should be weighed against the increased eradication rates and increased potential for toxicity demonstrated by some other classes of approved agents (see CLINICAL STUDIES.)

Uncomplicated Pyelonephritis: caused by E. coli.

*Although treatment of infections due to this organism in this organ system demonstrated a clinically acceptable overall outcome, efficacy was studied in fewer than 10 infections.

Culture and susceptibility testing should be performed when appropriate to determine the causative organism and its susceptibility to loracarbef. Therapy may be started while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly.

DOSAGE AND ADMINISTRATION

Loracarbef is administered orally either at least 1 hour prior to eating or at least 2 hours after eating. The recommended dosages, durations of treatment, and applicable patient populations are described in TABLE 13.

TABLE 13
Population/ Infection Dosage (mg) Duration (days)

    Adults (13 years and older)

    Lower Respiratory Tract

   
 Secondary Bacterial Infection of Acute Bronchitis 200-400 q12h 7
 Acute Bacterial Exacerbation of Chronic
 Bronchitis
400 q12h 7
 Pneumonia 400 q12h 14

    Upper Respiratory Tract

 Pharyngitis/Tonsillitis 200 q12h 10*
 Sinusitis‡ 400 q12h 10

    Skin and Skin Structure

   
 Uncomplicated Skin and Skin Structure Infections 200 q12h 7

    Urinary Tract

   
 Uncomplicated cystitis‡ 200 q24h 7
 Uncomplicated pyelonephritis 400 q12h 14

    Pediatric Patients (6 months to 12 years)

    Upper Respiratory Tract

   
 Acute Otitis Media 30 mg/kg/day in divided doses q12h 10
 Acute maxillary sinusitis‡ 30 mg/kg/day in divided doses q12h 10
 Pharyngitis/Tonsillitis 15 mg/kg/day in divided doses q12h 10*

    Skin and Skin Structure

   
 Impetigo 15 mg/kg/day in divided doses q12h 7
* In the treatment of infections due to S. pyogenes, Lorabid should be administered for at least 10 days.
Otitis media should be treated with the suspension. Clinical studies of otitis media were conducted with the suspension formulation only. The suspension is more rapidly absorbed than the capsules, resulting in higher peak plasma concentrations when administered at the same dose. Therefore, the capsule should not be substituted for the suspension in the treatment of otitis media (see CLINICAL PHARMACOLOGY).
(See CLINICAL STUDIES and

INDICATIONS

AND USAGE
for further information.)


TABLE 14 Pediatric Dosage Chart Daily Dose 15 mg/kg/day
    100 mg/5 ml Suspension 200 mg/5 ml Suspension
Weight Dose given twice daily Dose given twice daily
lb kg ml tsp ml tsp
15 7 2.6 0.5 --- ---
29 13 4.9 1.0 2.5 0.5
44 20 7.5 1.5 3.8 0.75
57 26 9.8 2.0 4.9 1.0


TABLE 15 Pediatric Dosage Chart Daily Dose 30 mg/kg/day
    100 mg/5 ml Suspension 200 mg/5 ml Suspension
Weight Dose given twice daily Dose given twice daily
lb kg ml tsp ml tsp
15 7 5.2 1.0 2.6 0.5
29 13 9.8 2.0 4.9 1.0
44 20 --- --- 7.5 1.5
57 26 --- --- 9.8 2.0


Renal Impairment: Loracarbef may be administered to patients with impaired renal function. The usual dose and schedule may be employed in patients with creatinine clearance levels of 50 ml/min or greater. Patients with creatinine clearance between 10 and 49 ml/min may be given half of the recommended dose at the usual dosage interval, or the normal recommended dose at twice the usual dosage interval. Patients with creatinine clearance levels less than 10 ml/min may be treated with the recommended dose given every 3 to 5 days; patients on hemodialysis should receive another dose following dialysis.

When only the serum creatinine is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance (CLcr, ml/min). The equation assumes the patient's renal function is stable.

Males = [(weight in kg) ´ (140 - age)] ¸ [72 ´ serum creatinine (mg/100 ml)] Females = (0.85) ´ (above value) Reconstitution Directions for Oral Suspension

  • 50 ml: Add 30 ml of water in 2 portion to the dry mixture in the bottle. Shake well after each addition.
  • 75 ml: Add 45 ml of water in 2 portions to the dry mixture in the bottle. Shake well after each addition.
  • 100 ml: Add 60 ml of water in 2 portions to the dry mixture in the bottle. Shake well after each addition.

After mixing, the suspension may be kept at room temperature, 59° to 86°F (15° to 30°C), for 14 days without significant loss of potency. Keep tightly closed. Discard unused portion after 14 days.

HOW SUPPLIED

Lorabid (loracarbef) Pulvules: 200 mg, is blue and gray with 3170.

Lorabid (loracarbef) Pulvules: 400 mg, is blue and pink with 3171.

Keep tightly closed. Store at controlled room temperature, 59° to 86°F (15° to 30°C). Protect from heat.

Pulves oral suspension is strawberry bubble gum flavor.

PRODUCT LISTING

    Capsule - Oral - 200 mg

30's $94.35

    Lorabid (loracarbef) Pulvules, Lilly

00002-3170-30

    Capsule - Oral - 400 mg

30's $121.46

    Lorabid (loracarbef) Pulvules, Lilly

00002-3171-30

    Powder For Reconstitution - Oral - 100 mg/5 ml

50 ml $15.07

    Lorabid (loracarbef) , Lilly

00002-5135-87

100 ml $26.84

    Lorabid (loracarbef) , Lilly

00002-5135-48

    Powder For Reconstitution - Oral - 200 mg/5 ml

50 ml $25.16

    Lorabid (loracarbef) , Lilly

00002-5136-87

75 ml $35.22

    Lorabid (loracarbef) , Lilly

00002-5136-18

100 ml $40.28

    Lorabid (loracarbef) , Lilly

00002-5136-48


REFERENCES

1. National Committee for Clinical Laboratory Standards, M2-A4 performance standards for antimicrobial disk susceptibility tests. ed 4, Villanova, PA, April, 1990.

2. National Committee for Clinical Laboratory Standards, M7-A2 methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, ed 2, Villanova, PA, April, 1990.

Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied
A A A

Lorabid - User Reviews

Lorabid User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Lorabid sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.